^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesna

    Company:
    Generic mfg.
    Drug class:
    Antioxidant
    Related drugs:
    1d
    An evidence-based approach to pericardial synovial sarcoma: a unique case report. (PubMed, Ecancermedicalscience)
    The chemotherapy regimen of ifosfamide, mesna and doxorubicin proved effective for this condition, leading to a significant reduction in tumour size and metabolic activity. However, due to disease recurrence and the presence of a KDM5A-positive marker, second-line therapy with trabectedin and pazopanib became necessary.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • KDM5A (Lysine Demethylase 5A) • CD99 (CD99 Molecule) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    doxorubicin hydrochloride • pazopanib • ifosfamide • Yondelis (trabectedin) • mesna
    7d
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan
    7d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    23d
    Extraskeletal Ewing Sarcoma Mimicking Benign Soft Tissue Tumors: A Rare Case. (PubMed, Cureus)
    Following multidisciplinary discussion, the patient was initiated on adjuvant chemotherapy using the CAV-IE (cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide), with a plan to complete 12 cycles, while radiotherapy was not indicated. She commenced her treatment with Cycle 1 of the IE component, accompanied by supportive care including intravenous fluids, ondansetron, omeprazole, and dexamethasone...She developed dysuria during hospitalization, and the treatment plan was adjusted to include an increased dose of mesna to enhance uroprotection. This case highlights the importance of considering EES in the differential diagnosis of persistent soft tissue masses, even in slow-growing lesions. It underscores the pivotal role of immunohistochemistry and multidisciplinary management in achieving a definitive diagnosis and favorable outcomes.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • VIM (Vimentin) • CD99 (CD99 Molecule)
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • dexamethasone • mesna • omeprazole • ondansetron intravenous
    1m
    Off-the-shelf NK Cells + SCT for Myeloid Malignancies (clinicaltrials.gov)
    P2, N=24, Completed, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P2
    Phase classification
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene)
    |
    TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • Chr del(5q)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    1m
    Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov)
    P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • temozolomide • tamoxifen • cytarabine • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • thiotepa • Neupogen (filgrastim) • celecoxib oral
    2ms
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    2ms
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    |
    cyclophosphamide • fludarabine IV • mesna • SJCAR19
    3ms
    A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24). (PubMed, Clin Lung Cancer)
    Durvalumab combined with doxorubicin and ifosfamide suggested clinical activity in recurrent and/or metastatic PSC. Larger studies are warranted to confirm benefits and refine treatment strategies.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • doxorubicin hydrochloride • ifosfamide • mesna
    3ms
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov)
    P1/2, N=260, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2027 --> Jun 2028
    Trial completion date
    |
    IGH (Immunoglobulin Heavy Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    3ms
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    3ms
    IS-free Treg HaploHCT (clinicaltrials.gov)
    P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30 | Trial completion date: Dec 2030 --> Aug 2029 | Trial primary completion date: Dec 2029 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa